Proposal #	Clinical trial(s) from which specimens were requested	Proposal Principal Investigator/ Institution	Publication Title	PMID
CSC0003	E3805	Nima Sharifi/ Cleveland Clinic Foundation	HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer	32053149
CSC0005	E2197	Hannah Gilmore/ Univ. Hospitals Case Medical Center	Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation	34362928
CSC0011	S0816	David Scott/ British Columbia Cancer Agency	Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study	30723079
CSC0013	S1107	Przemyslaw W. Twardowski/ City of Hope National Medical Center	Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107	30334014
CSC0014	E3805	Christopher Sweeney/ Dana-Farber Cancer Institute	Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial	34129855

Proposal #	Clinical trial(s) from which specimens were requested	Proposal Principal Investigator/ Institution	Publication Title	PMID
CSC0017	RTOG 0424	Arnab Chakravarti/ Ohio State University	- Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial; - Long-Term Report of a Comprehensive Molecular and Genomic Analysis in NRG Oncology/RTOG 0424: A Phase II Study of Radiation and Temozolomide in High-Risk Grade II Glioma	29955793; 34589661
CSC0019	S0800	Lajos Pusztai/ Yale Cancer Center	- Tumor-Infiltrating Lymphocytes and PD-L1 Expression in Pre- and Posttreatment Breast Cancers in the SWOG S0800 Phase II Neoadjuvant Chemotherapy Trial; - Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial	29588392; 30967156
CSC0025	NSABP B-31	S. Rim Kim/ NRG Oncology	Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast Cancer	30888406
CSC0027	CALGB-10603	Richard Stone/ Dana-Farber Cancer Institute	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia	31826241
CSC0028	E3805	Christopher Sweeney/ Dana-Farber Cancer Institute	Impact of baseline serum IL-8 on metastatic hormone-sensitive prostate cancer outcomes in the Phase 3 CHAARTED trial (E3805)	32949185

Proposal #	Clinical trial(s) from which specimens were requested	Proposal Principal Investigator/ Institution	Publication Title	PMID
CSC0029	NCIC-MA.27	James Ingle/ Mayo Clinic	Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α	32098767
CSC0032	E1900	Tomasz Skorski/ Temple University	- Inhibition of the mutated c-KIT kinase in AML1-ETO-positive leukemia cells restores sensitivity to PARP inhibitor; - TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors; - TGFβR-SMAD3 Signaling Induces Resistance to PARP Inhibitors in the Bone Marrow Microenvironment	31816060; 34215619; 33027668
CSC0037	RTOG 0521	William A. Hall/ Medical College of Wisconsin	The Influence of the Pretreatment Immune State on Response to Radiation Therapy in High-Risk Prostate Cancer: A Validation Study From NRG/RTOG 0521	35675855
CSC0043	CALGB 89803	William Grady/ Fred Hutchinson Cancer Center	Evaluation of methylated DCR1 as a biomarker for response to adjuvant irinotecan-based therapy in stage III colon cancer: cancer and leukaemia Group B 89803 (Alliance)	35412430
CSC0050	RTOG 92-02, RTOG 9413, RTOG 9902	Felix Feng/ University of California, San Francisco & Paul Nguyen/ Dana-Farber Cancer Institute/Brigham & Women's Hospital	Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials	36596347

Proposal #	Clinical trial(s) from which specimens were requested	Proposal Principal Investigator/ Institution	Publication Title	PMID
CSC0064	GOG-0218	Angeles Alvarez Secord/ Duke Cancer Institute	Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218	31919136
CSC0065	NSABP B-34	Alexander H.G. Paterson/ Tom Baker Cancer Center, Calgary	MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice	34377934
CSC0075	RTOG 9601	Felix Feng/ University of California, San Francisco & Phuoc T. Tran/ Johns Hopkins University	Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial	33570548
CSC0082	S0226	James Rae/ University of Michigan	Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial	34521624

Proposal #	Clinical trial(s) from which specimens were requested	Proposal Principal Investigator/ Institution	Publication Title	PMID
CSC0083	RTOG 0126	Daniel Spratt/ University of Michigan, Jeff Michalski/ Washington University, Felix Feng/ University of California, San Francisco	Genomic Classifier Performance in Intermediate-Risk Prostate Cancer: Results From NRG Oncology/RTOG 0126 Randomized Phase 3 Trial	37137444
CSC0092	NSABP B-42	Terry Mamounas/ Orlando Health-University of Florida Health Cancer Center & Priya Rastogi/ University of Pittsburgh	Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial	38376912
CSC0095	S0106	Jerry Radich/ Fred Hutchinson Cancer Center	Quantification of measurable residual disease using duplex sequencing in adults with acute myeloid leukemia	37534515
CSC0097	NSABP B-42	Terry Mamounas/ Orlando Health-University of Florida Health Cancer Center	Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial	39047219

Proposal #	Clinical trial(s) from which specimens were requested	Proposal Principal Investigator/ Institution	Publication Title	PMID
CSC0102	S0221	Daniel Hertz/ University of Michigan	- Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221; - Pre-treatment amino acids and risk of paclitaxel-induced peripheral neuropathy in SWOG S0221	37935109; 38814343
CSC0115	NSABP B-31	Nadine Norton/ Mayo Clinic Florida	Replication of genetic associations of chemotherapy-related cardiotoxicity in the adjuvant NSABP B-31 clinical trial	37305569
CSC0118	RTOG 9512	Quynh-Thu Le/ Stanford University	Association between Locoregional Failure and NFE2L2/KEAP1/CUL3 Mutations in NRG/RTOG 9512: A Randomized Trial of Radiation Fractionation in T2N0 Glottic Cancer	39656603
CSC0122	CALGB 89803	Stacey Cohen/ Fred Hutchinson Cancer Center	Evaluating the utility of ZNF331 promoter methylation as a prognostic and predictive marker in stage III colon cancer: results from CALGB 89803 (Alliance)	38716804
CSC0129	CALGB 40601	Matthew Ellis/ Baylor	Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers	40480221
CSC0147	CALGB 90601	Jonathan E. Rosenberg/ Memorial Sloan Kettering Cancer Center	Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance)	40256659
CSC0148	GOG-0258	Aine Clements/ Riverside Methodist Hospital, OH	Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258	39854806

Proposal #	Clinical trial(s) from which specimens were requested	Proposal Principal Investigator/ Institution	Publication Title	PMID
CSC0154	C9741	W. Fraser Symmans, MD, MD Anderson, TX, & Otto Metzger, MD, DFCI	Adjuvant Dose-Dense Chemotherapy in Hormone Receptor-Positive Breast Cancer	39746162
CSC0185	CALGB-90601	Jonathan E. Rosenberg, MSKCC	Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance)	40256659
CSC0201	A031201	Charles Ryan, MD, University of Minnesota	- Penalized weighted proportional hazards model for robust variable selection and outlier detection; - Joint Modelling of Longitudinal Measurements and Time-to-Event Outcomes With a Cure Fraction Using Functional Principal Component Analysis; - Pathogenic Genomic Alterations in Circulating Tumor DNA Predict Overall Survival in Men with Metastatic Castrate-resistant Prostate Cancer	35581736; 39633601; 40774853